Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group

Johannes J M Kwakman; Erik van Werkhoven; Lieke H J Simkens; Johan M van Rooijen; Yes A J van de Wouw; Albert J Ten Tije; Geert-Jan M Creemers; Mathijs P Hendriks; Maartje Los; Robbert J van Alphen; Marco B Polée; Erik W Muller; Ankie M T van der Velden; Theo van Voorthuizen; Miriam Koopman; Linda Mol; Cornelis J A Punt

doi:10.1016/j.clcc.2019.01.002

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group

Clin Colorectal Cancer. 2019 Jun;18(2):e229-e230. doi: 10.1016/j.clcc.2019.01.002. Epub 2019 Jan 29.

Authors

Johannes J M Kwakman¹, Erik van Werkhoven², Lieke H J Simkens³, Johan M van Rooijen⁴, Yes A J van de Wouw⁵, Albert J Ten Tije⁶, Geert-Jan M Creemers⁷, Mathijs P Hendriks⁸, Maartje Los⁹, Robbert J van Alphen¹⁰, Marco B Polée¹¹, Erik W Muller¹², Ankie M T van der Velden¹³, Theo van Voorthuizen¹⁴, Miriam Koopman¹⁵, Linda Mol¹⁶, Cornelis J A Punt¹⁷

Affiliations

¹ Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: j.j.kwakman@amc.uva.nl.
² Department of Biometrics, The Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
³ Department of Medical Oncology, Maxima Medical Center, Eindhoven, the Netherlands.
⁴ Department of Medical Oncology, Martini Hospital, Groningen, the Netherlands.
⁵ Department of Medical Oncology, VieCuri Medical Center, Venlo, the Netherlands.
⁶ Department of Medical Oncology, Amphia Hospital, Breda, the Netherlands.
⁷ Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
⁸ Department of Medical Oncology, Northwest Clinics, Alkmaar, the Netherlands.
⁹ Department of Medical Oncology, Sint Antonius Hospital, Nieuwegein, the Netherlands.
¹⁰ Department of Medical Oncology, TweeSteden Hospital, Tilburg, the Netherlands.
¹¹ Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
¹² Department of Medical Oncology, Slingeland Hospital, Doetinchem, the Netherlands.
¹³ Department of Medical Oncology, Tergooi Hospital, Hilversum, the Netherlands.
¹⁴ Department of Medical Oncology, Rijnstate Hospital, Arnhem, the Netherlands.
¹⁵ Department of Medical Oncology, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.
¹⁶ Clinical Trial Department, Netherlands Comprehensive Cancer Organisation (IKNL), Nijmegen, the Netherlands.
¹⁷ Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

PMID: 30782413
DOI: 10.1016/j.clcc.2019.01.002

No abstract available

Publication types

Clinical Trial, Phase III
Comparative Study
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bevacizumab / administration & dosage
Bevacizumab / adverse effects
Capecitabine / administration & dosage*
Capecitabine / adverse effects
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / mortality
Colorectal Neoplasms / pathology
Drug Administration Schedule
Drug Combinations
Follow-Up Studies
Hand-Foot Syndrome / epidemiology*
Hand-Foot Syndrome / etiology
Humans
Incidence
Kaplan-Meier Estimate
Oxonic Acid / administration & dosage*
Oxonic Acid / adverse effects
Progression-Free Survival
Tegafur / administration & dosage*
Tegafur / adverse effects

Substances

Drug Combinations
S 1 (combination)
Tegafur
Bevacizumab
Oxonic Acid
Capecitabine

Associated data

ClinicalTrials.gov/NCT01918852